ES2095975T3 - Uso de combinaciones de polisacaridos gelificantes y substratos portadores de medicamento, finamente divididos, para composiciones oftalmicas de uso topico. - Google Patents

Uso de combinaciones de polisacaridos gelificantes y substratos portadores de medicamento, finamente divididos, para composiciones oftalmicas de uso topico.

Info

Publication number
ES2095975T3
ES2095975T3 ES92105334T ES92105334T ES2095975T3 ES 2095975 T3 ES2095975 T3 ES 2095975T3 ES 92105334 T ES92105334 T ES 92105334T ES 92105334 T ES92105334 T ES 92105334T ES 2095975 T3 ES2095975 T3 ES 2095975T3
Authority
ES
Spain
Prior art keywords
combinations
ophthalmic compositions
polysaccharides
gelificant
medicinally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92105334T
Other languages
English (en)
Inventor
Paul Joseph Tracy Missel
Rajni Jani
John C Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of ES2095975T3 publication Critical patent/ES2095975T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE COMBINACIONES DE POLISACARIDOS GELIFICANTES Y SUBSTRATOS PORTADORES DE MEDICAMENTOS FINAMENTE DIVIDIDOS EN COMPOSICIONES OFTALMICAS TOPICAS. SE DESVELAN COMPOSICIONES OFTALMICAS QUE COMPRENDEN COMBINACIONES DE POLISACARIDOS GELIFICANTES Y SUBSTRATOS PORTADORES DE MEDICAMENTOS FINAMENTE DIVIDIDOS QUE SE VUELVEN RELATIVAMENTE MAS VISCOSOS AL ENTRAR EN CONTACTO CON EL OJO. TAMBIEN SE DESCRIBEN OTRAS COMPOSICIONES OFTALMICAS QUE COMPRENDEN UN MEDICAMENTO FARMACEUTICAMENTE ACTIVO, COMO OCURRE CON LAS FORMAS DE EMPLEO.
ES92105334T 1991-03-27 1992-03-27 Uso de combinaciones de polisacaridos gelificantes y substratos portadores de medicamento, finamente divididos, para composiciones oftalmicas de uso topico. Expired - Lifetime ES2095975T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67614691A 1991-03-27 1991-03-27

Publications (1)

Publication Number Publication Date
ES2095975T3 true ES2095975T3 (es) 1997-03-01

Family

ID=24713413

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92105334T Expired - Lifetime ES2095975T3 (es) 1991-03-27 1992-03-27 Uso de combinaciones de polisacaridos gelificantes y substratos portadores de medicamento, finamente divididos, para composiciones oftalmicas de uso topico.

Country Status (9)

Country Link
EP (1) EP0507224B1 (es)
JP (1) JP2536806B2 (es)
AT (1) ATE144701T1 (es)
AU (1) AU654175B2 (es)
CA (1) CA2064160C (es)
DE (1) DE69214863T2 (es)
DK (1) DK0507224T3 (es)
ES (1) ES2095975T3 (es)
GR (1) GR3022385T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625903B1 (en) * 1992-02-21 1998-08-12 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
JPH07508030A (ja) * 1992-05-13 1995-09-07 アルコン　ラボラトリーズ，インコーポレイテッド カルシウムアンタゴニストと公知の抗緑内障薬との組合せを含む眼局所用組成物
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
WO1996037191A1 (en) * 1995-05-24 1996-11-28 Alcon Laboratories, Inc. Antibacterial compositions
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
AU740874B2 (en) * 1997-06-26 2001-11-15 Merck & Co., Inc. Method for optimizing retinal and optic nerve health
PL199321B1 (pl) * 2000-07-28 2008-09-30 Alcon Inc Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
CA2456833A1 (en) * 2001-08-10 2003-02-20 Masahiro Inohara Polysaccharide-containing compositions and use thereof
KR20040073503A (ko) * 2001-12-21 2004-08-19 알콘, 인코퍼레이티드 안과용 및 이과용 약제학적 조성물의 점도 및 기타물리학적 성질을 개질시키기 위한 무기 나노입자의 용도
BR0215238A (pt) * 2001-12-21 2005-05-31 Alcon Inc Uso de nanopartìculas inor ânicas sintéticas como veìculos para drogas oftálmicas e óticas
JP4725699B2 (ja) * 2002-04-08 2011-07-13 ライオン株式会社 眼科用組成物及び眼科用組成物配合用防腐剤
WO2005018646A1 (ja) * 2003-08-21 2005-03-03 Sucampo Ag 眼科用組成物
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
HUE058931T2 (hu) 2018-04-24 2022-09-28 Allergan Inc Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
GB202008919D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Polysaccharide conpositions and therapeutic gels
IT202200021852A1 (it) 2022-10-21 2024-04-21 Montefarmaco Otc S P A Composizione liquida oftalmica viscosa comprendente gomme ed estratti naturali
WO2026042047A1 (en) * 2024-08-23 2026-02-26 Johnson & Johnson Vision Care, Inc. Compositions and articles comprising reversible complexes of crosslinked carrageenan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
AU651655B2 (en) * 1991-01-15 1994-07-28 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions

Also Published As

Publication number Publication date
JPH0710776A (ja) 1995-01-13
CA2064160C (en) 1998-08-11
EP0507224A2 (en) 1992-10-07
ATE144701T1 (de) 1996-11-15
DE69214863T2 (de) 1997-04-10
DK0507224T3 (da) 1997-04-07
EP0507224B1 (en) 1996-10-30
GR3022385T3 (en) 1997-04-30
AU1386392A (en) 1992-10-01
AU654175B2 (en) 1994-10-27
EP0507224A3 (en) 1992-10-28
JP2536806B2 (ja) 1996-09-25
DE69214863D1 (de) 1996-12-05
CA2064160A1 (en) 1992-09-28

Similar Documents

Publication Publication Date Title
ES2095975T3 (es) Uso de combinaciones de polisacaridos gelificantes y substratos portadores de medicamento, finamente divididos, para composiciones oftalmicas de uso topico.
TWI262797B (en) Gelling ophthalmic compositions containing xanthan gum
AU5259793A (en) Antiallergic composition for opthalmic or nasal use
CA2160447A1 (en) Amino(thio)ether derivatives
FI955215A0 (fi) Hallitusti vapauttavat oksibutyniinivalmisteet
MY105121A (en) Pharmaceutical composition for systemic transdermal administration.
CA2379605A1 (en) Topical suspension formulations containing ciprofloxacin and dexamethasone
UA26303A1 (uk) Фармацевтичhа композиція, яка має імуhосупресорhу та аhтимікробhу активhість
CA2168097A1 (en) Substituted 2-aminotetralins
AU7266991A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
EP0045617A3 (en) Pharmaceutical composition
AU582584B2 (en) N-acetyl-neurominic acid expectorants
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
ATE191845T1 (de) Pharmazeutische träger zur topischen ophthalmischen anwendung
AU646439B2 (en) Novel retinoids
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
EP0378413A3 (en) Compositions for topical treatment of skin disorders
NO922282D0 (no) Formulering for vedvarende frigivelse av acetazolamid, samt fremgangsmaate for fremstilling av formuleringen
EP0114048A3 (en) Use of d,l and d-carazolole as an antiglaucoma agent, and pharmaceutical compositions containing them
NO985079L (no) Eksplosiv formulering
AU3080092A (en) Slow-release ibuprofen-containing medicament and its use
ES2131482A1 (es) Formulacion acuosa de bambuterol.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
EP0676206A4 (es)
AU8079891A (en) Bile alcohol and drug containing the same as active ingredient

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 507224

Country of ref document: ES